Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACUMEN PHARMACEUTICALS, INC.

(ABOS)
  Report
Delayed Nasdaq  -  04:00:00 2023-01-27 pm EST
5.450 USD   -1.27%
01/04Acumen Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
01/04Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
GL
01/04Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Acumen Pharmaceuticals Shares Rise After FDA Designation

10/24/2022 | 08:41am EST

By Dean Seal


Shares of Acumen Pharmaceuticals Inc. were up 10% to $8.41 in premarket trading Monday after the company said regulators granted fast-track designation to its Alzheimer's disease treatment.

The U.S. Food and Drug Administration gave the designation to ACU193, a clinical-stage monoclonal antibody. Acumen is currently studying the drug in a Phase 1 trial examining safety and proof of mechanism.

The designation facilitates development and expedites the review of drugs that treat serious or life-threatening conditions and fill unmet medical needs.

Chief Executive Officer Daniel O'Connell said Acumen is encouraged by the designation and looks forward to further collaboration with the FDA.

The shares are up 13% so far this year.


Write to Dean Seal at dean.seal@wsj.com


(END) Dow Jones Newswires

10-24-22 0840ET

All news about ACUMEN PHARMACEUTICALS, INC.
01/04Acumen Pharmaceuticals, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
01/04Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
GL
01/04Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors
AQ
01/04Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to Its Board of Directors
CI
2022Credit Suisse Trims Acumen Pharmaceuticals' Price Target to $16 From $17, Keeps Outperf..
MT
2022ACUMEN PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
2022Transcript : Acumen Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 14, 202..
CI
2022Acumen Pharmaceuticals, Inc. : Results of Operations and Financial Condition, Regulation F..
AQ
2022Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
2022Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highli..
GL
More news
Analyst Recommendations on ACUMEN PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -41,0 M - -
Net cash 2022 129 M - -
P/E ratio 2022 -5,54x
Yield 2022 -
Capitalization 223 M 223 M -
EV / Sales 2022 -
EV / Sales 2023 -
Nbr of Employees 16
Free-Float 84,4%
Chart ACUMEN PHARMACEUTICALS, INC.
Duration : Period :
Acumen Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACUMEN PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 5,45 $
Average target price 15,83 $
Spread / Average Target 191%
EPS Revisions
Managers and Directors
Daniel J. O'Connell President, Chief Executive Officer & Director
W. Matthew Zuga Chief Financial & Business Officer
Eric Siemers Chief Medical Officer
Kasey Spencer Director-Information Technology
Russell Barton Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ACUMEN PHARMACEUTICALS, INC.0.93%223
MODERNA, INC.7.58%72 745
LONZA GROUP AG17.24%42 787
IQVIA HOLDINGS INC.12.00%42 622
ALNYLAM PHARMACEUTICALS, INC.-2.55%28 465
SEAGEN INC.9.46%26 117